The Research Market and the Business of Genomics | GenomeWeb

While genomics may be inching toward the clinic, from a business perspective, the research end-market remains the prime target for most entrepreneurs in the space, writes Art Wuster at his Sequenomics blog.

Wuster looked at 72 firms listed on the technology company database Crunchbase, all of which received at least some third-party funding, and found that 38 were companies with customers in research laboratories or in other genomic firms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.